Last reviewed · How we verify
V - C - C+V
V-C-C+V is a combination vaccine containing inactivated varicella-zoster virus and other viral components designed to provide immunization against varicella (chickenpox) and related viral infections.
V-C-C+V is a combination vaccine containing inactivated varicella-zoster virus and other viral components designed to provide immunization against varicella (chickenpox) and related viral infections. Used for Varicella (chickenpox) prevention, Immunization against varicella-zoster virus.
At a glance
| Generic name | V - C - C+V |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Drug class | Inactivated viral vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a combination immunization product that stimulates the adaptive immune system to generate protective antibodies and cellular immunity against varicella-zoster virus. The vaccine formulation contains inactivated viral antigens that trigger both humoral and cell-mediated immune responses, conferring protection against primary varicella infection and potentially reducing severity of herpes zoster in vaccinated individuals.
Approved indications
- Varicella (chickenpox) prevention
- Immunization against varicella-zoster virus
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Myalgia
- Headache
Key clinical trials
- Conventional vs Pulsed RF in Coccydynia (NA)
- Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (PHASE1)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Graphene Far-infrared Intervention Study of Cognitive Status in Older Adults (NA)
- Clinical Assessment of Viscosity-Modified Composite Resins: Preheated, Sonic Activated, and Flowable Resins in Class V Restorations (NA)
- Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |